Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity

@article{Vejpongsa2014Topoisomerase2A,
  title={Topoisomerase 2$\beta$: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity},
  author={P. Vejpongsa and Eth Yeh},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2014},
  volume={95}
}
Anthracyclines are powerful chemotherapy agents that are still widely used today. However, their clinical use is limited by the development of dose‐dependent cardiotoxicity. Recently, we showed that topoisomerase 2β (Top2β) is required for anthracycline to induce DNA double‐strand breaks and changes in the transcriptome, leading to mitochondrial dysfunction and generation of reactive oxygen species. Furthermore, deleting Top2β from cardiomyocytes prevented the development of anthracycline… Expand
View on Wiley
ncbi.nlm.nih.gov
129 Citations
Highly Influential Citations
5
Background Citations
43
Methods Citations
2
Results Citations
3

129 Citations

Citation Type

Citation Type

Review Statins in Anthracycline-induced Cardiotoxicity: Rac and Rho, and the Heartbreakers Official Journal of the Cell Death Differentiation Association
  • 2017
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature.
Cardiotoxicity of anthracycline therapy: current perspectives
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
  • R. Damiani, D. Moura, +4 authors J. Saffi
  • Chemistry, Medicine
  • Toxicology in vitro : an international journal published in association with BIBRA
  • 2018
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets
Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*
New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells
Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.
...
1
2
3
4
5
...